Average Insider

Where insiders trade, we follow

$ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Healthcare
Sector
Biotechnology
Industry
Jerome Benedict Durso
CEO
59
Employees
$1.39
Current Price
$393.63M
Market Cap
52W Low$1.38
Current$1.390.2% above low, 99.8% below high
52W High$6.44

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys11$14,187.0010,000All Buys
Sells00--
2 weeksBuys44$96,431.0960,700All Buys
Sells00--
1 monthBuys44$96,431.0960,700All Buys
Sells00--
2 monthsBuys44$96,431.0960,700All Buys
Sells00--
3 monthsBuys44$96,431.0960,700All Buys
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 18, 2026
MENZIUSO RICHARD THOMAS
Principal Accounting Officer
Purchase10,000$1.42$14,187.00View Details
Nov 13, 2026
WEAVER GREGORY L
Chief Financial Officer
Purchase10,000$1.62$16,200.00View Details
Nov 13, 2026
Pisano Wayne
Director
Purchase10,000$1.64$16,350.00View Details
Nov 13, 2026
Durso Jerome Benedict
Director
Purchase30,700$1.62$49,694.09View Details
11 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 12, 2026
EPS
Estimated-$0.13
Actual-$0.15
Miss
Revenue
Estimated$1.75K
ActualN/A
Nov 5, 2026
EPS
Estimated-$0.14
ActualN/A
Revenue
Estimated$1.75K
ActualN/A
2 more earnings records available โ€” create a free account to see 12 months of history

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.11.1